Characterization of alterations of Rb2/p130 tumor suppressor in all-trans-retinoic acid resistant SK-OV3 ovarian carcinoma cells

2008 ◽  
Vol 217 (1) ◽  
pp. 77-85 ◽  
Author(s):  
Anthonise Louis Fields ◽  
Dianne Robert Soprano ◽  
Kenneth J. Soprano
Keyword(s):  
Retinoic Acid ◽  
Tumor Suppressor ◽  
Ovarian Carcinoma ◽  
Carcinoma Cells ◽  
Ovarian Carcinoma Cells ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid: Result of the Randomized MRC Trial

Blood ◽  
1999 ◽  
Vol 93 (12) ◽  
pp. 4131-4143 ◽  
Author(s):  
Alan K. Burnett ◽  
David Grimwade ◽  
Ellen Solomon ◽  
Keith Wheatley ◽  
Anthony H. Goldstone
Keyword(s):  
Retinoic Acid ◽  
Promyelocytic Leukemia ◽  
Rt Pcr ◽  
Blood Cell Count ◽  
Relapse Risk ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid ◽  
To Receive ◽  
Risk Of Relapse

Abstract All-trans retinoic acid (ATRA) is an essential component of the treatment of acute promyelocytic leukemia (APL), but the optimal timing and duration remain to be determined. Molecular characterization of this disease can refine the diagnosis and could be potentially useful in monitoring response to treatment. Patients defined morphologically to have APL were randomized to receive a 5-day course of ATRA before commencing chemotherapy or to receive daily ATRA commencing with chemotherapy and continuing until complete remission (CR). The chemotherapy was that used in current MRC Leukaemia Trials. Outcome comparisons were by intention to treat with additional analysis for relevant risk factors. Patients were characterized by molecular techniques for the fusion products of the t(15;17) and monitored by reverse transcriptase-polymerase chain reaction (RT-PCR) during and after treatment. Two hundred thirty-nine patients were randomized. Treatment with extended ATRA resulted in a superior remission rate (87% v 70%, P < .001), due to fewer early and induction deaths (12% v 23%, P = .02), and less resistant disease (2% v 7%, P = .03), which was associated with a significantly more rapid recovery of neutrophils and platelets. Extended ATRA reduced relapse risk (20%v 36% at 4 years, P = .04) and resulted in superior survival (71% v 52% at 4 years, P = .005). Presenting white blood cell count (WBC) was a key determinant of outcome. The 70% of patients who presented with a WBC less than 10 × 109/L had a better CR (85% v62%, P = .0001) and reduced relapse risk (22% v42%, P = .002) and superior survival (69%v 43%, P < .0001). Within the low count group, extended ATRA resulted in a better CR (94% v 76%, P= .001), reduced relapse risk (13% v 35%, P = .04), and improved survival (80% v 57%, P = .0009). There was no evidence of benefit in patients presenting with a higher WBC (>10 × 109/L). Molecular monitoring after the third chemotherapy course had a correlation with risk of relapse. The relapse risk was 57% if the RT-PCR was positive versus 27% if the RT-PCR was negative (P = .006). APL patients who present with a low WBC derive substantial benefit from combining ATRA with induction chemotherapy until remission is achieved, whereas patients with a higher WBC did not benefit. Molecular characterization of disease can improve diagnostic precision and a positive RT-PCR after consolidation identifies patients at a higher risk of relapse.

Preparation and characterization of micelles of oligomeric chitosan linked to all-trans retinoic acid

2012 ◽  
Vol 87 (2) ◽  
pp. 1176-1184 ◽  
Author(s):  
Ali Fattahi ◽  
Mohammad-Ali Golozar ◽  
Jaleh Varshosaz ◽  
Hamid Mirmohammad Sadeghi ◽  
Mohammadhossein Fathi
Keyword(s):  
Retinoic Acid ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

Anticancer activity of all- trans retinoic acid-loaded liposomes on human thyroid carcinoma cells

2017 ◽  
Vol 150 ◽  
pp. 408-416 ◽  
Author(s):  
Maria Chiara Cristiano ◽  
Donato Cosco ◽  
Christian Celia ◽  
Andra Tudose ◽  
Rosario Mare ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Thyroid Carcinoma ◽  
Anticancer Activity ◽  
Carcinoma Cells ◽  
Human Thyroid ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

Interaction of liposome-associated all-trans-retinoic acid with squamous carcinoma cells

1994 ◽  
Vol 34 (6) ◽  
pp. 527-534 ◽  
Author(s):  
Ranjani Parthasarathy ◽  
Peter G. Sacks ◽  
Daniel Harris ◽  
Heidi Brock ◽  
Kapil Mehta
Keyword(s):  
Retinoic Acid ◽  
Squamous Carcinoma ◽  
Carcinoma Cells ◽  
Squamous Carcinoma Cells ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

scholarly journals Protein Phosphatase 2A Associates with Rb2/p130 and Mediates Retinoic Acid-induced Growth Suppression of Ovarian Carcinoma Cells

2003 ◽  
Vol 278 (43) ◽  
pp. 41881-41889 ◽  
Author(s):  
Scott Vuocolo ◽  
Enkhtsetseg Purev ◽  
Dongmei Zhang ◽  
Jiri Bartek ◽  
Klaus Hansen ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Ovarian Carcinoma ◽  
Protein Phosphatase ◽  
Protein Phosphatase 2A ◽  
Growth Suppression ◽  
Carcinoma Cells ◽  
Ovarian Carcinoma Cells ◽  
Phosphatase 2A
Sign in / Sign up

Export Citation Format

Share Document